Why Viking Therapeutics Stock Zoomed 5% Higher Today

The clinical-stage biotech, closely watched by some because of its investigational weight-loss drug VK2735, saw its share price improve by more than 5% as a result. By contrast, the S&P 500 index basically traded flat across the trading session. The company is a front-runner in the race to develop an orally administered weight loss drug. Good news from a peer and a positive analyst update were the elements driving Viking Therapeutics (VKTX 5.07%) stock higher on the first trading day of the week. Companies ...